Description
DaVita’s Hidden Growth Engine: Integrated Kidney Care Earnings Exceed Expectations!
DaVita Inc.’s third quarter 2026 results reflect a combination of ongoing clinical advancements, strategic investments, and operational challenges. The company emphasized significant progress in clinical outcomes, particularly through innovations in fluid management and expanded hemodialysis (HD) dialyzers. These initiatives have contributed to mortality improvements and enhanced patient quality of life, with expanded HD showing promising adoption rates (over 90% among eligible patients) and positive feedback from both patients and physicians. However, the financial benefits from these clinical advancements are expected to materialize gradually, with network-wide rollout commencing in November and meaningful volume and mortality-related gains anticipated primarily from the second half of 2028 onward. Financially, DaVita reported adjusted operating income of $561 million and adjusted earnings per share of $3.82 for the quarter, with free cash flow at $276 million. U.S. dialysis volume grew 1.



